NIH ACTIV initiative launches adaptive clinical trials of blood-clotting treatments for COVID-19

As part of its Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, NIH is exploring whether blood thinners might help treat the infection.

As part of its Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, NIH is exploring whether blood thinners might help treat the infection. Researchers began considering anticoagulants as a therapeutic option after noticing that many patients who died from COVID-19 suffered unusual clotting that spawned life-threatening complications. Now, Operation Warp Speed has provided funding for a series of Phase III clinical trials to assess the use of different types of blood thinners in this patient population. NIH's National Heart, Lung, and Blood Institute will oversee the three studies, one of which will target adults who have been discharged after being hospitalized for moderate to severe COVID-19. The two other studies, which are already in progress, focus separately on infected adults who currently are hospitalized and on outpatients. The investigations boast adaptive design, meaning the study intervention may be adjusted in response to emerging trial data. The studies will be conducted at 100-plus sites worldwide, in hopes of gaining important insight that could inform the care of patients with COVID-19.